International Symposium On Medication-Related Osteonecrosis of the Jaws (MRONJ)

MRONJ is an irreversible and potentially serious adverse effect of anti-resorptive and anti-angiogenic drugs, which can lead to chronic pain, infection, disfigurement and reduced quality of life.

Professor Fedele has been awarded research funding to lead an international network of hospital and academic partners in identifying predisposing genetic variants for the disease through a Genome Wide Association study (GWAs).

They have recruited and collected DNA from over 900 patients with MRONJ and have successfully completed the discovery of a number of potentially associated genetic variants.

The group are currently working on replication analysis. The final results of the study will be available in November 2017.

Pictured (L-R): Dr Morten Schiod, Dr Sven Otto, Dr Roman Guggenberge, Dr Ourania Nicolatou-Galiti, Dr Stefano Fedele, Dr Alberto Bedogni and Dr Thomas Kofod.